Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.460
+0.010 (0.69%)
At close: Apr 7, 2026, 4:00 PM EDT
1.460
0.00 (0.00%)
After-hours: Apr 7, 2026, 4:00 PM EDT
Pyxis Oncology Employees
Pyxis Oncology had 56 employees as of December 31, 2025. The number of employees increased by 12 or 27.27% compared to the previous year.
Employees
56
Change (1Y)
12
Growth (1Y)
27.27%
Revenue / Employee
$247,464
Profits / Employee
-$1,421,804
Market Cap
91.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 56 | 12 | 27.27% |
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Sep 30, 2024 | 54 | -13 | -19.40% |
| Jun 30, 2024 | 55 | -17 | -23.61% |
| Mar 31, 2024 | 51 | -22 | -30.14% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Sep 30, 2023 | 67 | -6 | -8.22% |
| Jun 30, 2023 | 72 | 5 | 7.46% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Sep 30, 2022 | 73 | 28 | 62.22% |
| Jun 30, 2022 | 67 | 29 | 76.32% |
| Mar 31, 2022 | 64 | 26 | 68.42% |
| Dec 31, 2021 | 56 | - | - |
| Sep 30, 2021 | 45 | - | - |
| Jun 30, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Verrica Pharmaceuticals | 76 |
| Seres Therapeutics | 66 |
| Aardvark Therapeutics | 40 |
| Vivani Medical | 37 |
| Q32 Bio | 24 |
| TuHURA Biosciences | 22 |
| Coya Therapeutics | 8 |
PYXS News
- 15 days ago - Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - GlobeNewsWire
- 3 months ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 3 months ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 5 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 6 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire